The insider sales are too small to signal material bearishness. Monitor for any further insider selling or clinical updates on Danon disease, which is the next major catalyst. The stock's low price near $3.60 may attract speculative interest ahead of H2 2026 data.
RCKT drugs
RCKT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $3.25entry
- T+1 · 6mo ago −5.54%α −5.48% · $3.07
- T+5 · 6mo ago −8.92%α −9.89% · $2.96
- T+20 · 5mo ago −12.00%α −14.12% · $2.86
- T+60 · 3mo ago +7.69%α +3.18% · $3.50
Price Chart
How similar events traded
Executive Summary
Rocket Pharmaceuticals CEO Gaurav Shah sold $10K worth of shares and another insider sold $68K, totaling $78K in open-market sales over a 7-day window. This follows the Q1 earnings report showing a narrowed net loss and the $180M PRV monetization, but the stock trades near $3.60 with a $393M market cap. The insider sales are modest (0.02% of market cap) and likely driven by routine portfolio management rather than a bearish signal, especially given the recent positive catalyst.
Key Financial Metrics
Key Facts
- CEO Gaurav Shah sold 2,728 shares at $3.606 for ~$10K on May 13, 2026.
- Sarbani Chaudhuri sold 17,600 shares at $3.84 for ~$68K on May 7, 2026.
- Total insider sales of $78K represent ~0.02% of RCKT's $393M market cap.
- Q1 2026 net loss improved to -$47.6M from -$61.3M YoY; KRESLADI approved and PRV monetized for $180M.
- Cash runway extended into Q2 2028; Danon disease Phase 2 update expected H2 2026.
Financial Impact
Insider sales of $78K are trivial relative to $393M market cap (0.02%).
Risk Factors
- Further insider selling could erode confidence if it accelerates.
- Danon disease trial failure would be a major setback.
- Cash burn remains high despite extended runway.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RCKT-1778790001885 |
Track record
21 reports on RCKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers